hVIVO (LON:HVO) Shares Up 13% - What's Next?

Key Points

• Shares of hVIVO plc rose by 13% during mid-day trading, reaching a high of GBX 8 ($0.11) and closing at GBX 7.80 ($0.10) with significantly increased trading volume.
• Analysts have mixed views on hVIVO, with Shore Capital reducing their price target from GBX 35 to GBX 25 while Peel Hunt maintains an "add" rating with a GBX 21 target; overall, the stock holds an average rating of "Buy."
• hVIVO specializes in human challenge clinical trials for vaccine and antiviral testing, supporting major pharmaceuticals and public health organizations with trials for various conditions including COVID-19 and flu.

hVIVO plc (LON:HVO - Get Free Report)'s share price shot up 13% during mid-day trading on Monday . The company traded as high as GBX 8 ($0.11) and last traded at GBX 7.80 ($0.10). 9,588,585 shares traded hands during trading, an increase of 223% from the average session volume of 2,969,923 shares. The stock had previously closed at GBX 6.90 ($0.09).

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on HVO. Shore Capital reduced their price objective on shares of hVIVO from GBX 35 to GBX 25 and set a "buy" rating on the stock in a research note on Tuesday, September 23rd. Peel Hunt restated an "add" rating and issued a GBX 21 price target on shares of hVIVO in a research note on Tuesday, July 29th. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, hVIVO has an average rating of "Buy" and an average target price of GBX 23.

hVIVO Trading Up 13.0%

The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61. The firm has a market cap of £53.60 million, a P/E ratio of 1,012.99 and a beta of 0.97. The business's fifty day moving average is GBX 9.24 and its 200-day moving average is GBX 11.96.

hVIVO (LON:HVO - Get Free Report) last released its earnings results on Tuesday, September 23rd. The company reported GBX (0.29) earnings per share for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. Analysts predict that hVIVO plc will post 1.5492958 EPS for the current year.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.